As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Study of Omega-3 Replacement with Krill Oil in Treatment of Systemic Lupus Erythematosus

Clinical Trial Title: 
Study to assess clinical benefit of omega-3 replacement with krill oil in disease management of SLE.
Clinical Trial Protocol ID: 
18022805
Clinical Trial Investigator Name: 
Meenakshi Jolly, MD
Clinical Trial Protocol Description: 

The study is a 24 week randomized, double-blind controlled multicenter study followed by an open label extension treatment for another 24 weeks. The purpose of this study is to determine whether the correction of the omega-3 deficiency may reduce disease activity in SLE patients.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a clinical diagnosis of systemic lupus erythematosus (SLE).

You will be excluded from the study if any of the following criteria apply to you:

  • Have rapidly progressive neurologic or renal disease.
  • Are using an omega-3 prescription drug (e.g. Lovaza®, Vascepa®, etc.) or as medical food (e.g. Vascazen®, Vayarin, Onemia™ etc.).
  • Are currently using or have recently used (within 3 months of screening) any OTC fish or krill oil dietary supplement, or any long-chain omega-3 fatty acid dietary supplement (e.g., MegaRed).

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Arthritis and Other Rheumatic Diseases
Contact Phone: 
(312) 563-2955
Contact Name: 
Joshlean Fair